Online inquiry

IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11689MR)

This product GTTS-WQ11689MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets influenza B virus hemagglutinin gene. The antibody can be applied in Influenza B infection research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NP_056660.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 956538
UniProt ID P03460
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11689MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3280MR IVTScrip™ mRNA-Anti-alpha toxin&lukE, ASN-1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ASN-1
GTTS-WQ11485MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MetMAb
GTTS-WQ15711MR IVTScrip™ mRNA-Anti-S, VIR-7831(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA VIR-7831
GTTS-WQ11377MR IVTScrip™ mRNA-Anti-IGF, MEDI-573(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MEDI-573
GTTS-WQ9415MR IVTScrip™ mRNA-Anti-PTPRC, Iomab-B(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA Iomab-B
GTTS-WQ14530MR IVTScrip™ mRNA-Anti-IL6R, SA-237(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SA-237
GTTS-WQ4571MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986004
GTTS-WQ446MR IVTScrip™ mRNA-Anti-PDGFRA, 3G3(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 3G3
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW